Illumina (ILMN) Inks Deal To Commercialize NGS-Based IVD Kits
Zacks Investment Research | Oct 09, 2019 08:37AM ET
Illumina, Inc. (NASDAQ:ILMN) recently announced that it collaborated with QIAGEN N.V. (NYSE:QGEN) to expand the availability and use of NGS-based In-Vitro Diagnostic (“IVD”) test kits, including companion diagnostics, for patient management.
Per the agreement, the companies will work to commercialize an array of medically documented steps, combining QIAGEN’s content and bioinformatics solutions. Initially, the partnership is expected to focus on commercializing oncology IVD kits to support patient management. This may be expanded at a later stage to include clinical diagnostic fields such as cardiology and hereditary diseases.
With the partnership, Illumina aims to strengthen global foothold in genomic sequencing through IVD tests and companion diagnostics.
Significance of the Collaboration
Per terms of the agreement, Illumina will provide QIAGEN non-exclusive rights to develop and commercialize IVD kits on a global scale. Illumina’s management believes that the partnership is a breakthrough to carry forward the use of next-generation sequencing (NGS) to achieve favorable patient outcomes.
The agreement also includes rights for expanding the partnership on future Illumina diagnostic (Dx) systems. The companies also plan to look for opportunities to develop and market companion diagnostics based on Illumina’s TruSight Oncology (“TSO”) menu, which will enable all-inclusive genomic profiling of tumor samples in immunotherapy.
The collaboration is expected to boost Illumina’s strong IVD portfolio.
A Peek Into Illumina’s IVD Portfolio
The company has a robust diagnostic NGS product portfolio, which includes MiSeq Dx and NextSeq 550Dx platforms. The IVD test kits will be used in consonance with these platforms.
Recent Developments
Illumina signed a partnership deal with Adaptive Biotechnologies Corporation (NASDAQ:ADPT) (a commercial-stage biotechnology company) in September 2019, which will enable clinicians to carry out clinical immunodiagnostic testing that can be conducted in local laboratories.
In the same month, Illumina entered an agreement with the Broad Institute of MIT and Harvard to work on the development of secondary genomic analysis algorithms and software.
Get The News You Want
Illumina also announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, NGS-based approach to noninvasive prenatal testing (NIPT), in June 2019.
Industry Prospects
Per a report by Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.